Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE SULFATE versus PLAQUENIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE SULFATE versus PLAQUENIL.
HYDROXYCHLOROQUINE SULFATE vs PLAQUENIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimalarial and immunosuppressive agent. Accumulates in lysosomes, raising pH, impairing antigen processing and presentation. Inhibits toll-like receptor signaling and cytokine production (e.g., IL-6, TNF-α). Interferes with quinone reductase activity and heme polymerization in plasmodia.
Antimalarial and immunosuppressant; inhibits heme polymerase in Plasmodium, preventing conversion of toxic heme to hemozoin; also inhibits lysosomal function, antigen presentation, and cytokine production (e.g., IL-1, TNF-alpha) in autoimmune diseases.
200-400 mg orally once daily or divided twice daily; maximum 600 mg/day or 6.5 mg/kg/day (whichever is lower). For malaria: 800 mg loading dose, then 400 mg at 6, 24, and 48 hours.
400 mg (310 mg base) orally daily, or 400 mg/day in divided doses; maintenance: 200-400 mg/day
None Documented
None Documented
Terminal half-life: ~40–50 days (range 30–60 days) due to extensive tissue distribution. Steady-state reached after 4–6 months.
Terminal elimination half-life: 32-50 days (range 22-124 days) due to extensive tissue distribution and slow release from melanin-rich tissues; requires long-term dosing to achieve steady state (3-6 months).
Renal: ~50% unchanged; Hepatic metabolism: ~50% (desethylchloroquine, desethylhydroxychloroquine); Fecal: minimal (<5%).
Renal (50-70% unchanged), fecal (20-30% as metabolites), minor biliary.
Category A/B
Category C
Antimalarial / DMARD
Antimalarial